I’ve been looking at BOT over the last few months and their MC of $700m, obviously a very different product (a cream that stops excessive sweating) but they recently received FDA approval in June and have now laid out a plan via Telehealth to and traditional sales to be in market late 2025, soft launch earlier in the year.
I see us following a similar trajectory, with FDA approval we should be at a minimum, 3x our current price. $6 ✅ BOT had FDA approval priced in and that may also happen with us and it’s a low bar for approval and should easily get over the line.
Obviously, Spontan will have a higher price point and in the short term larger potential market. (I do however see a day where everyone is buying a anti-sweat cream from their local chemist)
I don’t hold BOT yet as I’ve “gone in hard” on LTP, topping up when we hit $1.45 last month.
Things are about to heat up.
DYOR GLTAH
LTP Price at posting:
$2.06 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)